According to Zacks, “G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company’s product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. “
Separately, Needham & Company LLC reiterated a “buy” rating and set a $44.00 price target on shares of G1 Therapeutics in a research note on Thursday, April 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $37.00.
G1 Therapeutics (NASDAQ:GTHX – Get Rating) last issued its quarterly earnings results on Wednesday, May 4th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.17). G1 Therapeutics had a negative return on equity of 107.75% and a negative net margin of 708.20%. During the same quarter in the previous year, the business earned ($0.65) EPS. Analysts expect that G1 Therapeutics will post -3.81 EPS for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in the stock. Swiss National Bank increased its stake in shares of G1 Therapeutics by 9.1% during the first quarter. Swiss National Bank now owns 70,400 shares of the company’s stock worth $535,000 after buying an additional 5,900 shares during the period. Fisher Asset Management LLC increased its stake in G1 Therapeutics by 1.9% in the first quarter. Fisher Asset Management LLC now owns 2,311,138 shares of the company’s stock valued at $17,565,000 after purchasing an additional 43,064 shares during the last quarter. Nordea Investment Management AB increased its stake in G1 Therapeutics by 1.4% in the first quarter. Nordea Investment Management AB now owns 397,746 shares of the company’s stock valued at $3,126,000 after purchasing an additional 5,636 shares during the last quarter. Barclays PLC raised its holdings in G1 Therapeutics by 291.7% during the fourth quarter. Barclays PLC now owns 65,513 shares of the company’s stock worth $669,000 after purchasing an additional 48,788 shares in the last quarter. Finally, BlackRock Inc. lifted its position in shares of G1 Therapeutics by 2.1% during the 4th quarter. BlackRock Inc. now owns 3,310,212 shares of the company’s stock worth $33,799,000 after buying an additional 68,127 shares during the last quarter. Hedge funds and other institutional investors own 61.89% of the company’s stock.
G1 Therapeutics Company Profile (Get Rating)
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.
- Get a free copy of the StockNews.com research report on G1 Therapeutics (GTHX)
- Institutional Support For Tyson Foods Is Growing
- Time to Buy These 3 Oversold Mid-Caps
- Johnson Outdoors Falls On Bleak Outlook
- Mattel Stock is Ready to Catch
- HCA Healthcare Stock is Ready to Climb Higher
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.